Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology CongressBusiness Wire · Oct 1, 2026
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 CongressBusiness Wire · Sep 23, 2026
Evommune Halts Atopic Dermatitis Program Following Trial FailureBenzinga · Sep 9, 2026
Evommune scraps eczema drug after trial miss, shares plungeReuters · Sep 8, 2026
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic DermatitisBusiness Wire · Sep 8, 2026
Brokerages Set Evommune, Inc. (NYSE:EVMN) PT at $43.25Defense World · Aug 11, 2026Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.